A Phase 2 interventional study of Rotigotine nasal spray and Placebo in Parkinson's Disease, sponsored by UCB Pharma. Completed. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-10-02.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 26th largest by enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2006, is one of 7 in phase 2, and was the 6th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 5 started in 2006.
This study's enrollment of 82 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
44 studies in Parkinson Disease by UCB S.A.: none open now, none under way, none of them phase 3. Of 44 finished, 29 (66%) have results posted.
Among the 44 studies in Parkinson Disease by UCB S.A., this one is the 23rd largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2006, is one of 5 in phase 2, and was the 9th registered.
UCB S.A.’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 44 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this trial is to evaluate safety and efficacy of rotigotine nasal spray (SPM 952) in a single dose application scheme.
Subjects will undergo a 2 - 28 days screening period in which eligibility criteria will be checked. Subjects will then be hospitalized for one night. In the morning of the next day, subjects will be randomly assigned either to rotigotine or placebo nasal spray and will then receive a single dose of trial medication. Safety assessments after application include adverse events, 12-lead electrocardiograms, blood pressure and heart rate assessments, and laboratory checks. Efficacy will be assessed by application of motor examination scores.
The first subject is planned to be enrolled in February 2006. The last subject is planned to be enrolled in May 2006. Last subject out is expected for August 2006.
The objective of this trial is to evaluate safety and efficacy of rotigotine nasal spray (SPM 952)in a single dose application scheme. Subjects will undergo a 2-28 days screening period in which eligibility criteria will be checked. Subjects will then be hospitalized for one night. In the morning of the next day, subjects will be randomly assigned either to rotigotine or placebo nasal spray and will then receive a single dose of trial medication. Safety assessments after application include adverse events, 12-lead electrocardiograms, blood pressure and heart rate assessments, and laboratory checks. Efficacy will be assessed by application of motor examination scores.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo nasal spray 1 - 4 puffs
Other: Placebo
Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)
Drug: Rotigotine nasal spray
Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)
Drug: Rotigotine nasal spray
Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)
Drug: Rotigotine nasal spray
Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)
Drug: Rotigotine nasal spray
Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries
Also known as: Neupro, SPM 952
placebo nasal spray 1, 2 3, and 4 puffs
Number of Subjects Who Complete the Trial
Time frame: 15 days
Change From Baseline at 24 Minutes Post-dose in Unified Parkinson Disease Rating Scale (UPDRS) Part III Motor Examination
The Unified Parkinson's Disease Rating Scale (UPDRS) is a scale for the assessment of function in Parkinson's disease. UPDRS Part III measures Motor Examination. Range: 0 (Best score possible) to 56 (Worst score possible) Change = 24 minute value minus baseline value.
Time frame: Baseline, and 24 minutes post-dose
Change From Baseline to 34 Minutes Post-dose in Tapping Rate (Taps/Min)
One-minute tapping rate will be calculated as the number of times a subject could tap on two 4 x 4 cm marks placed on a board 30 cm apart during 1 minute (30 cm measured from the inner border of the two boxes).
Time frame: Baseline and 34 minutes post-dose
"Success Rate" (Percentage of Subjects Achieving "Off" Reversals)
Subjects reversing from "off" to "on" following initiation of treatment. "On" and "off" state refer to periods where Parkinson's disease symptoms are not present ("on") and periods where symptoms are present ("off"); the "on"/"off" determination at each assessment timepoint was made by the investigator.
Time frame: Up to 6 hours post-dose
Time of First "Off" Reversal
Number of minutes to first reversal of symptoms from "off" to "on". Estimated via Kaplan-Meier estimation method. "On" and "off" state refer to periods where Parkinson's disease symptoms are not present ("on") and periods where symptoms are present ("off"); the "on"/"off" determination at each assessment timepoint was made by the investigator.
Time frame: Up to 6 hours post-dose
| Milestone | Placebo 1-4 Puffs | Rotigotine 1 Puff | Rotigotine 2 Puffs | Rotigotine 3 Puffs | Rotigotine 4 Puffs |
|---|---|---|---|---|---|
| Started | 17 | 16 | 16 | 17 | 16 |
| Completed | 17 | 16 | 16 | 17 | 16 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| participants | Placebo 1-4 Puffs | Rotigotine 1 Puff | Rotigotine 2 Puffs | Rotigotine 3 Puffs | Rotigotine 4 Puffs |
|---|---|---|---|---|---|
| Number of Subjects Who Complete the Trial | 17 | 16 | 16 | 17 | 16 |
The Unified Parkinson's Disease Rating Scale (UPDRS) is a scale for the assessment of function in Parkinson's disease. UPDRS Part III measures Motor Examination. Range: 0 (Best score possible) to 56 (Worst score possible) Change = 24 minute value minus baseline value.
| score on a scale | Placebo 1-4 Puffs | Rotigotine 1 Puff | Rotigotine 2 Puffs | Rotigotine 3 Puffs | Rotigotine 4 Puffs |
|---|---|---|---|---|---|
| Baseline | 35.1 ± 7.77 | 37.2 ± 10.68 | 39.5 ± 12.94 | 36.2 ± 7.60 | 37.6 ± 9.30 |
| 24 minutes post-dose | 25.3 ± 12.44 | 30.0 ± 11.35 | 29.2 ± 13.53 | 29.1 ± 8.51 | 26.4 ± 12.95 |
| Change from baseline to 24 minutes post-dose | -9.8 ± 7.8 | -7.2 ± 10.32 | -10.3 ± 6.17 | -7.1 ± 6.47 | -11.6 ± 10.65 |
One-minute tapping rate will be calculated as the number of times a subject could tap on two 4 x 4 cm marks placed on a board 30 cm apart during 1 minute (30 cm measured from the inner border of the two boxes).
| taps per minute | Placebo 1-4 Puffs | Rotigotine 1 Puff | Rotigotine 2 Puffs | Rotigotine 3 Puffs | Rotigotine 4 Puffs |
|---|---|---|---|---|---|
| Baseline | 112.7 ± 47.08 | 109.8 ± 28.94 | 127.2 ± 44.33 | 115.9 ± 41.05 | 118.3 ± 40.41 |
| 34 minutes post-dose | 141.2 ± 50.92 | 131.0 ± 30.01 | 138.7 ± 44.42 | 142.9 ± 51.20 | 144.4 ± 57.64 |
| Change from baseline to 34 minutes post-dose | 28.5 ± 27.83 | 21.2 ± 26.69 | 11.5 ± 11.27 | 27.1 ± 25.25 | 22.9 ± 27.75 |
Subjects reversing from "off" to "on" following initiation of treatment. "On" and "off" state refer to periods where Parkinson's disease symptoms are not present ("on") and periods where symptoms are present ("off"); the "on"/"off" determination at each assessment timepoint was made by the investigator.
| percentage of participants | Placebo 1-4 Puffs | Rotigotine 1 Puff | Rotigotine 2 Puffs | Rotigotine 3 Puffs | Rotigotine 4 Puffs |
|---|---|---|---|---|---|
| Reversed from "off" to "on" (success) | 70.6 | 50.0 | 75.0 | 70.6 | 75.0 |
| Did not reverse from "off" to "on" | 29.4 | 50.0 | 25.0 | 29.4 | 25.0 |
Number of minutes to first reversal of symptoms from "off" to "on". Estimated via Kaplan-Meier estimation method. "On" and "off" state refer to periods where Parkinson's disease symptoms are not present ("on") and periods where symptoms are present ("off"); the "on"/"off" determination at each assessment timepoint was made by the investigator.
| minutes | Placebo 1-4 Puffs | Rotigotine 1 Puff | Rotigotine 2 Puffs | Rotigotine 3 Puffs | Rotigotine 4 Puffs |
|---|---|---|---|---|---|
| Time of First "Off" Reversal | 50 (24 to 65) | 60 (40 to 60) | 51 (22 to 84) | 50 (35 to 70) | 59 (35 to 190) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo 1-4 Puffs | — | 0/13 (0%) | 3/13 (23.1%) |
| Rotigotine 1 Puff | — | 0/17 (0%) | 9/17 (52.9%) |
| Rotigotine 2 Puffs | — | 1/17 (5.9%) | 5/17 (29.4%) |
| Rotigotine 3 Puffs | — | 0/18 (0%) | 9/18 (50%) |
| Rotigotine 4 Puffs | — | 1/17 (5.9%) | 9/17 (52.9%) |
| Event | Placebo 1-4 Puffs | Rotigotine 1 Puff | Rotigotine 2 Puffs | Rotigotine 3 Puffs | Rotigotine 4 Puffs |
|---|---|---|---|---|---|
| BradycardiaCardiac disorders | 0/13 | 0/17 | 0/17 | 0/18 | 1/17 |
| DepressionPsychiatric disorders | 0/13 | 0/17 | 1/17 | 0/18 | 0/17 |
| Event | Placebo 1-4 Puffs | Rotigotine 1 Puff | Rotigotine 2 Puffs | Rotigotine 3 Puffs | Rotigotine 4 Puffs |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/13 | 0/17 | 0/17 | 0/18 | 3/17 |
| Application site reactionGeneral disorders | 0/13 | 1/17 | 3/17 | 0/18 | 2/17 |
| DizzinessNervous system disorders | 1/13 | 1/17 | 1/17 | 1/18 | 3/17 |
| SomnolenceNervous system disorders | 1/13 | 2/17 | 2/17 | 3/18 | 1/17 |
| VomitingGastrointestinal disorders | 0/13 | 0/17 | 0/17 | 0/18 | 2/17 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/13 | 0/17 | 0/17 | 0/18 | 2/17 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/13 | 0/17 | 0/17 | 0/18 | 2/17 |
| Application site irritationGeneral disorders | 0/13 | 1/17 | 0/17 | 2/18 | 0/17 |
| Atrioventricular block first degreeCardiac disorders | 1/13 | 0/17 | 0/17 | 0/18 | 0/17 |
| Urinary tract infectionInfections and infestations | 1/13 | 1/17 | 1/17 | 1/18 | 1/17 |
| Age, Categorical(Participants) | Placebo 1-4 Puffs | Rotigotine 1 Puff | Rotigotine 2 Puffs | Rotigotine 3 Puffs | Rotigotine 4 Puffs | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 8 | 5 | 9 | 10 | 41 |
| >=65 years | 8 | 8 | 11 | 8 | 6 | 41 |
| Age, Continuous(years) | Placebo 1-4 Puffs | Rotigotine 1 Puff | Rotigotine 2 Puffs | Rotigotine 3 Puffs | Rotigotine 4 Puffs | Total |
|---|---|---|---|---|---|---|
| Mean | 63.9 ± 6.94 | 67.1 ± 7.54 | 66.8 ± 9.67 | 63.9 ± 8.28 | 60.5 ± 8.04 | 64.4 ± 8.28 |
| Sex: Female, Male(Participants) | Placebo 1-4 Puffs | Rotigotine 1 Puff | Rotigotine 2 Puffs | Rotigotine 3 Puffs | Rotigotine 4 Puffs | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 5 | 4 | 7 | 4 | 24 |
| Male | 13 | 11 | 12 | 10 | 12 | 58 |
| Region of Enrollment(participants) | Placebo 1-4 Puffs | Rotigotine 1 Puff | Rotigotine 2 Puffs | Rotigotine 3 Puffs | Rotigotine 4 Puffs | Total |
|---|---|---|---|---|---|---|
| Germany | 11 | 12 | 12 | 10 | 13 | 58 |
| Austria | 2 | 2 | 1 | 4 | 1 | 10 |
| United Kingdom | 1 | 1 | 2 | 0 | 2 | 6 |
| Spain | 3 | 1 | 1 | 3 | 0 | 8 |
No study locations are listed for this record.
The record gives a start of Feb 2006, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine